An Oral Small Molecule PCSK9 Inhibitor Disclosed by AstraZeneca

Nurix Therapeutics' NX-1607, an oral CBL-B inhibitor, is in clinical trials to enhance T cell activation, addressing limitations of immune checkpoint inhibitors. Initial results presented at ACS Spring 2024.